Welcome to our dedicated page for Aptevo Therapeutics SEC filings (Ticker: APVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aptevo Therapeutics Inc. (APVO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret key points. As a Nasdaq-listed, clinical-stage biotechnology company focused on bispecific and trispecific immunotherapies, Aptevo uses SEC filings to report on its financial condition, capital structure, and material business developments.
Investors researching APVO can review Form 10-K annual reports and Form 10-Q quarterly reports (when available) to understand operating expenses, research and development spending, and liquidity. These periodic reports typically discuss the progress of clinical programs such as the RAINIER Phase 1b/2 trial of mipletamig in frontline acute myeloid leukemia and the development of ALG.APV-527 and other pipeline candidates built on the ADAPTIR and ADAPTIR-FLEX platforms.
Form 8-K current reports are especially relevant for Aptevo, as they disclose material events including quarterly financial results, equity financings, amendments to rights agreements, clinical milestones, and Nasdaq listing updates. Recent 8-Ks, for example, have referenced financial results for specific quarters, expansion of the CD3-engaging pipeline, and confirmation of compliance with Nasdaq stockholders’ equity requirements.
Aptevo’s registration statements, such as the Form S-1 filed in connection with a Standby Equity Purchase Agreement, provide detail on financing structures, potential share issuances, and risk factors. Proxy materials like the DEF 14A definitive proxy statement describe corporate governance matters, stock incentive plans, and stockholder approvals for actions such as reverse stock splits and equity facilities.
On Stock Titan, AI tools summarize lengthy filings to highlight items such as changes in stockholders’ equity, new financing agreements, and disclosures about the bispecific and trispecific oncology pipeline. Users can also track Form 4 insider transaction reports when filed, gaining visibility into equity transactions by Aptevo’s officers and directors.
By using this APVO filings page, investors can quickly navigate Aptevo’s SEC reporting history, from financial updates to clinical and capital markets disclosures, with AI-generated insights that clarify complex regulatory documents.
Schedule 13G filing for Aptevo Therapeutics Inc. (NASDAQ: APVO) discloses that a group of affiliated Yorkville entities, led by YA II PN, Ltd., now beneficially owns 357,842 common shares, equal to 9.99 % of the outstanding stock. The position consists entirely of shares that the investors have the right to acquire pursuant to a $25 million Standby Equity Purchase Agreement (SEPA) executed on 16 June 2025. The SEPA prohibits Aptevo from issuing additional shares to the group if doing so would push their aggregate ownership above the 9.99 % threshold.
- Voting/Dispositive power: 0 shares sole; 357,842 shares shared.
- Outstanding shares basis: 3,224,156 shares reported by the issuer on 20 June 2025 plus the 357,842 acquisition rights held by YA II.
- Reporting persons: YA II PN, YA Global Investments II (U.S.), Yorkville Advisors Global LP, related GPs, Mark Angelo, and SC-Sigma Global Partners.
Aptevo Therapeutics Inc. (APVO) – Schedule 13G filing dated 25 June 2025
The filing discloses the beneficial ownership position of three reporting persons – Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC – in the common stock of Aptevo Therapeutics.
- Initial position (18 Jun 2025): Under the Securities Purchase Agreement ("SPA") the group could have been deemed to own 82,000 shares, or 9.8 % of the then-outstanding 759,156 shares, with potential future ownership of up to 507,500 shares if two warrants (total 425,500 shares) were exercised and blocker provisions were waived.
- Current position (close of business 25 Jun 2025): The reporting persons now report 0 shares beneficially owned, equating to 0.00 % of the class. The share-count denominator used is 2,864,156 shares (759,156 existing + 2,105,000 newly issued at SPA closing).
- Warrant conditions: Both Intracoastal Warrant 1 (410,000 shares) and Warrant 2 (15,500 shares) remain unexercisable until shareholder approval and are each subject to a 9.99 % ownership blocker.
Key takeaways for investors
- The investors that were previously positioned to own almost 10 % of Aptevo now disclose no beneficial ownership, removing a potential large holder from the register.
- Potential dilution from 425,500 warrant shares remains possible, but only after shareholder approval and subject to the 9.99 % cap.
- No financial performance metrics are included; the filing is limited to ownership disclosure.
Schedule 13G highlights for Aptevo Therapeutics (APVO)
- Reporting persons—Bigger Capital Fund LP, Bigger Capital Fund GP, LLC and Michael Bigger—disclosed beneficial ownership of 285,000 common shares, equal to 9.95 % of the 2,864,156 shares that were outstanding immediately after the company’s June 2025 offering.
- The shares are held with shared voting and dispositive power; none of the reporting persons has sole power over the stock.
- In addition to the common shares, the group holds warrants that could convert into far more equity: (i) 12,875 pre-funded warrant shares (subject to a 9.99 % ownership cap) and (ii) 1,532,364 common-warrant shares (subject to a 4.99 % cap; 1,489,375 of these require shareholder approval before becoming exercisable).
- However, the filing states that as of the close of business on 20 June 2025 the reporting persons sold the common stock (including the pre-funded-warrant shares) and therefore now own <5 % of the company’s outstanding shares.
- Because the warrants cannot currently be exercised beyond the ownership caps, immediate dilution risk is limited, but if caps are waived or shareholder approval is obtained the potential issuance of up to 1.53 million shares represents a material overhang relative to the current float.
- The certification indicates the investment is passive and not intended to influence control.
Aptevo Therapeutics has announced its 2025 Annual Meeting of Stockholders to be held virtually on July 24, 2025. The company is presenting eight key proposals for stockholder consideration:
- Election of two directors to serve until 2028
- Ratification of Baker Tilly US as independent auditor
- Approval of a reverse stock split at a ratio between 1-for-6 to 1-for-22
- Authorization to issue >19.99% of common stock under Standby Equity Purchase Agreement with Yorkville
- Approval of Third Amended and Restated 2018 Stock Incentive Plan
- Advisory vote on 2024 executive compensation
- Approval to issue >19.99% of common stock related to warrant agreement from June 2025
- Authorization for meeting adjournment if needed
The virtual meeting will be held at www.virtualshareholdermeeting.com/APVO2025. Record date is June 20, 2025, with 3,224,156 shares eligible to vote. The Board recommends voting "FOR" all proposals.
Schedule 13G filing overview: On 18 June 2025, L1 Capital Global Opportunities Master Fund, Ltd. (“L1 Capital GO MF”) disclosed a passive stake in Aptevo Therapeutics Inc. (APVO).
- Shares owned: 285,000 common shares.
- Ownership percentage: 9.95 % of the 2,864,156 shares outstanding immediately after the company’s June 2025 offering (as cited in the issuer’s Rule 424(b)(4) prospectus).
- Voting & dispositive power: Sole power over all 285,000 shares; no shared power reported.
- Additional securities not counted in ownership figure: 1,489,375 common stock warrants, 12,875 pre-funded warrants, and 20,000 warrants purchased on 25 April 2025. These instruments are subject to a 4.99 % beneficial-ownership cap and therefore excluded from the 9.95 % calculation.
- Reporting party details: Cayman Islands entity; directors David Feldman and Joel Arber sign the filing and disclaim personal beneficial ownership beyond their indirect control.
- Certification: The filer states the securities were not acquired with the purpose of influencing control of APVO.
Implications for investors: The disclosure positions L1 Capital GO MF as a near-10 % holder, signalling institutional interest ahead of potential warrant exercises that could materially raise its economic exposure and, if later exempt from the 4.99 % cap, increase dilution. No change in management or business strategy is indicated; the filing is for passive ownership compliance.